Back to top

Image: Bigstock

The Zacks Analyst Blog Highlights: Coca-Cola, AT&T, Royal Dutch Shell, Facebook and Colgate-Palmolive

Read MoreHide Full Article

For Immediate Release

Chicago, IL – May 4, 2021 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: The Coca-Cola Company (KO - Free Report) , AT&T Inc. (T - Free Report) , Royal Dutch Shell plc (RDS.A - Free Report) , Facebook, Inc. (FB - Free Report) and Colgate-Palmolive Company (CL - Free Report) .

Here are highlights from Monday’s Analyst Blog:

Top Analyst Reports for Coca-Cola, AT&T and Royal Dutch Shell

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Coca-Cola Co., AT&T, and Royal Dutch Shell. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today's research reports here >>>

Shares of Coca-Cola have gained +2.2% in the past one month against the Zacks Beverages - Soft drinks industry's gain of +1.9%. The Zacks analyst believes that shares of Coca-Cola outpaced the industry in the past month, thanks to its robust earnings performance that continued in fourth-quarter 2020.

This marked the fifth straight quarter of earnings beat. Gains from aggressive cost management aided margins. Although the top line lagged estimates and declined on a year-over-year basis, the company's top line reflected improved trends compared with prior quarters.

However, continued pressures in the away-from-home channel, which account for nearly half of its revenues, affected revenues. Also, gains in the global value share in NARTD beverages was offset by negative channel mix.

(You can read the full research report on Coca-Cola here >>>)

Shares of AT&T have outperformed the Zacks Wireless National industry over the last six-month period (+16.2% vs. +9.8%). The Zacks analyst believes that AT&T is further well poised to gain from a solid subscriber growth on the back of a resilient customer-centric business model, driven by diligent execution of operational plans.

The company expects to continue investing in key areas while adjusting its business according to the evolving market scenario to fuel long-term growth with healthy dividend payment. It is likely to benefit from the streaming services of HBO Max, integrated fiber expansion and nationwide 5G deployment.

However, the company is facing a steady decline in linear TV subscribers, legacy services and wireline division. As it tries to woo customers with discounts and freebies, margins tend to fall. Spectrum crisis in a saturated wireless market and continued cord-cutting remain major headwinds.

(You can read the full research report on AT&T here >>>)

Shares of Royal Dutch Shell shares have underperformed the Zacks Oil & Gas Integrated industry over the year-to-date period (+8.1% vs +19.0%). However, the Zacks analyst believes that the company is poised for capital appreciation based on a slew of tailwinds. Shell's trading business has been instrumental in helping the supermajor partly cushion the impact of the coronavirus-induced oil price slump.

Further, the company's position as a key supplier of liquefied natural gas should benefit its long-term cash flow growth on the back of attractive growth opportunities. It is also making solid progress toward the transition to a renewable energy-focused future and pledged to attain zero-net emissions by 2050.

Meanwhile, the firm's high investment grade rating translates into low borrowing rates. Consequently, Shell is viewed as a preferred energy major to own now.

(You can read the full research report on Royal Dutch Shell here >>>)

Other noteworthy reports we are featuring today include Facebook and Colgate-Palmolive.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They're also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339                                                                        

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.